BCEL · Atreca, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $10.41M | $12.91M | $13.45M | - | $16.05M | $19.95M | $17.06M | - | $18.72M | $19.04M |
| SG&A | $5.39M | $6.83M | $8.08M | - | $7.25M | $8.08M | $8.61M | - | $8.80M | $8.03M |
| Total Operating Expenses | $36.65M | $19.75M | $21.53M | - | $23.29M | $28.03M | $25.67M | - | $27.52M | $27.07M |
| D&A | $900.0K | $1.30M | $1.29M | - | $1.40M | $1.40M | $1.35M | - | $1.40M | $1.20M |
| Operating Income | ($36.22M) | ($19.19M) | ($21.01M) | - | ($23.06M) | ($27.88M) | ($24.88M) | - | ($27.36M) | ($26.67M) |
| Interest Expense | - | - | - | - | - | - | - | - | $1.0K | $1.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | $1.0K |
| Net Income | ($36.22M) | ($19.19M) | ($21.01M) | - | ($23.06M) | ($27.88M) | ($24.88M) | - | ($27.36M) | ($26.68M) |
| EPS - Basic | ($0.92) | ($0.49) | ($0.54) | - | ($0.60) | ($0.72) | ($0.65) | - | ($0.66) | - |
| EPS - Diluted | ($0.92) | ($0.49) | ($0.54) | - | ($0.60) | ($0.72) | ($0.66) | - | ($0.74) | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.47M | $27.69M | $39.48M | $30.82M | $20.90M | $26.45M | $48.57M | $94.75M | $113.19M | $93.60M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.06M | $1.14M | $1.40M | $1.74M | $1.70M | $2.04M | $4.45M | $3.35M | $5.24M | $3.60M |
| Current Assets | $24.69M | $41.96M | $59.64M | $78.03M | $92.78M | $109.64M | $123.00M | $122.37M | $162.07M | $192.89M |
| Total Assets | $26.34M | $115.07M | $134.43M | $155.03M | $172.07M | $190.83M | $213.69M | $200.06M | $220.26M | $240.84M |
| Current Liabilities | $15.58M | $12.01M | $14.07M | $16.29M | $14.57M | $13.47M | $12.86M | $16.90M | $16.16M | $14.31M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $15.58M | $70.39M | $73.46M | $76.62M | $75.82M | $75.63M | $75.91M | $45.13M | $44.83M | $42.24M |
| Stockholders' Equity | $10.76M | $44.67M | $60.97M | $78.41M | $96.25M | $115.20M | $137.78M | $154.93M | $175.43M | $198.60M |
| Retained Earnings | ($533.34M) | ($497.12M) | ($477.93M) | ($456.92M) | ($435.58M) | ($412.52M) | ($384.64M) | ($359.77M) | ($330.25M) | ($302.89M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($14.44M) | - | - | - | ($25.55M) | - | - | - |
| Investing Cash Flow | - | - | $23.00M | - | - | - | ($24.39M) | - | - | - |
| Financing Cash Flow | - | - | $109.0K | - | - | - | $3.77M | - | - | - |
| CapEx | - | - | $80.0K | - | - | - | $68.0K | - | - | - |
| Free Cash Flow | - | - | ($14.52M) | - | - | - | ($25.62M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.69 | - | - | - | 1.03 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -137.5% | -16.7% | -15.6% | - | -13.4% | -14.6% | -11.6% | - | -12.4% | -11.1% |
| Return on equity | -336.6% | -42.9% | -34.5% | - | -24.0% | -24.2% | -18.1% | - | -15.6% | -13.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.58 | 3.49 | 4.24 | 4.79 | 6.37 | 8.14 | 9.57 | 7.24 | 10.03 | 13.48 |
| Quick ratio | 1.58 | 3.49 | 4.24 | 4.79 | 6.37 | 8.14 | 9.57 | 7.24 | 10.03 | 13.48 |
| Cash ratio | 0.86 | 2.31 | 2.81 | 1.89 | 1.43 | 1.96 | 3.78 | 5.61 | 7.01 | 6.54 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | -27358.0x | -26674.0x |
| Equity multiplier | 2.45 | 2.58 | 2.20 | 1.98 | 1.79 | 1.66 | 1.55 | 1.29 | 1.26 | 1.21 |
| Liabilities / Assets | 0.59 | 0.61 | 0.55 | 0.49 | 0.44 | 0.40 | 0.36 | 0.23 | 0.20 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -57.1% | 31.2% | 15.5% | - | 15.7% | -4.5% | 3.5% | - | -19.3% | -33.5% |
| Net income growth (YoY) | -57.1% | 31.2% | 15.5% | - | 15.7% | -4.5% | 3.5% | - | -19.3% | -33.5% |
| EPS growth (YoY) | -53.3% | 31.9% | 18.2% | - | 18.9% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 43.3% | - | - | - | 10.6% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -88.8% | -61.2% | -55.8% | -49.4% | -45.1% | -42.0% | -37.8% | -36.0% | -32.9% | 28.9% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Atreca against the 5 most active filers in the same SIC group.